GlassScriptPhysician profile
Ashwin G Gaitonde
NPI 1831395219
$33,021.48
in general payments reported to CMS, 2019-2025
36 companies · $6,877 in 2025
The $6,877 reported for 2025 was more than what 98% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $223 · 2021: $3,208 · 2022: $6,547 · 2023: $7,924 · 2024: $7,817 · 2025: $6,877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $20K · Food and Beverage: $2,789 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $19,744.25 |
| Food and Beverage | $2,788.68 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $29,047.94 | 2021-2025 | Nexplanon |
| Abbvie INC. | $766.44 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $551.62 | 2023-2025 | Myfembree |
| Pfizer INC. | $354.05 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $309.86 | 2021-2025 | |
| Astellas Pharma US INC | $251.44 | 2023-2025 | Veozah |
| Exeltis, USA INC. | $230.99 | 2019-2025 | Slynd |
| Coopersurgical, INC. | $171.18 | 2020-2025 | Summit Doppler, Endosee, Paragard T 380a |
| Myovant Sciences INC. | $131.25 | 2021-2022 | |
| Shield Therapeutics INC | $129.26 | 2022-2024 | |
| Hologic Sales and Service, LLC | $117.85 | 2022-2023 | Coolseal Generator, Myosure Tissue Removal Device, Acessa Provu System |
| Therapeuticsmd, INC. | $107.63 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $103.32 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $85.60 | 2019-2020 | |
| Allergan, INC. | $58.38 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $55.92 | 2021-2023 | Balcoltra |
| Daiichi Sankyo INC. | $53.06 | 2023 | Injectafer |
| Meditrina | $47.28 | 2022-2025 | |
| Lupin INC. | $42.87 | 2019-2021 | |
| Virtus Pharmaceuticals LLC | $41.49 | 2022 | |
| Amag Pharmaceuticals, INC. | $41.43 | 2019-2020 | |
| Dilon Technologies, INC. | $39.25 | 2025 | Hemoblast Bellows |
| Channel Medsystems, INC. | $35.43 | 2021 | |
| Sage Therapeutics, LLC | $32.10 | 2025 | Zurzuvae |
| Ethicon US, LLC | $30.64 | 2020-2023 | Echelon; Endopath, Echelon Endopath, Surgicel Nu-Knit |
| Vertical Pharmaceuticals, LLC | $23.88 | 2019 | |
| Exact Sciences Corporation | $23.88 | 2025 | The Cologuard Plus Collection Kit |
| Abbott Laboratories | $23.05 | 2022 | |
| Scynexis, INC. | $22.39 | 2022 | |
| Alexion Pharmaceuticals, INC. | $21.17 | 2022 | |
| Millicent US INC | $19.58 | 2020 | |
| Agile Therapeutics, INC. | $16.90 | 2022 | |
| Duchesnay USA Incorporated | $13.82 | 2019 | |
| Aspira Women'S Health INC | $13.81 | 2023 | Ova1 |
| Bolder Surgical LLC | $6.72 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashwin Gaitonde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.